Corpus ID: 53167613

[Retrospective Investigation of the Risk Factors for Severity in Panitumumab-Induced Hypomagnesemia].

@article{Nakazawa2018RetrospectiveIO,
  title={[Retrospective Investigation of the Risk Factors for Severity in Panitumumab-Induced Hypomagnesemia].},
  author={Yusuke Nakazawa and Naomi Ando and Dai Harada and Masaki Kitamura and Keisuke Aiba and Takashi Kawakubo},
  journal={Gan to kagaku ryoho. Cancer \& chemotherapy},
  year={2018},
  volume={45 10},
  pages={
          1435-1440
        }
}
Hypomagnesemia caused by panitumumab can often lead to severe adverse effects, such as arrhythmia. However, the risk factors are still controversial. To clarify the risk factors and time to onset of panitumumab-induced hypomagnesemia, we retrospectively investigated the records of 30 patients who had received panitumumab. They were divided into Grade B2 hypomagnesemia and non-Grade B2 hypomagnesemia groups, according to their serum magnesium levels, and we compared patients' backgrounds… Expand
1 Citations

Topics from this paper

Identifying optimal magnesium replenishment points based on risk of severe hypomagnesemia in colorectal cancer patients treated with cetuximab or panitumumab
TLDR
To minimize the risk of severe hypomagnesemia during anti-EGFR treatment, magnesium replenishment should be initiated in patients with pre-replenishment serum magnesium concentration, preferably before reaching intra-treatment concentrations of < 1.1 mg/dL. Expand